Jhanelle Gray, MD

BOARD CERTIFICATION:

FELLOWSHIP:
          •  H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL - Hematology/Oncology

RESIDENCY:
          •  The New York Presbyterian Hospital, New York, NY

MEDICAL SCHOOL:
          •  Weill Medical College of Cornell University, New York, NY - Medical Doctor

• Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR. Randomized International Phase III Trial of ERCC1 and RRM1 Expression-Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2013 May. Pubmedid: 23690416.


• Gray JE, Altiok S, Alexandrow MG, Walsh FW, Chen J, Schell MJ, Tai DF, Bepler G. Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers. Cancer. 2013 Mar;119(5):1023-1032. Pubmedid: 23065656. Pmcid: PMC3578040.


• Hall RD, Gray JE, Chiappori AA. Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer. Cancer Control. 2013 Jan;20(1):22-31. Pubmedid: 23302904.


• Alexandrow MG, Song LJ, Altiok S, Gray J, Haura EB, Kumar NB. Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer. Eur J Cancer Prev. 2012 Sep;21(5):407-412. Pubmedid: 22156994. Pmcid: PMC3319490.


• Jacobsen PB, Wells KJ, Meade CD, Quinn GP, Lee JH, Fulp WJ, Gray JE, Baz RC, Springett GM, Levine RM, Markham MJ, Schreiber FJ, Cartwright TH, Burke JM, Siegel RD, Malafa MP, Sullivan D. Effects of a brief multimedia psychoeducational intervention on the attitudes and interest of patients with cancer regarding clinical trial participation: a multicenter randomized controlled trial. J Clin Oncol. 2012 Jul;30(20):2516-2521. Pubmedid: 22614993.


• Gray J, Cubitt CL, Zhang S, Chiappori A. Combination of HDAC and topoisomerase inhibitors in small cell lung cancer. Cancer Biol Ther. 2012 Jun;13(8):614-622. Pubmedid: 22441819.


• Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, Gray J, Marks J, Ginsburg GS, Potti A, West M, Nevins JR, Lancaster JM. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol. 2012 Feb;30(6):678. Pubmedid: 22451975.


• Gray JE, Laronga C, Siegel EM, Lee JH, Fulp WJ, Fletcher M, Schreiber F, Brown R, Levine R, Cartwright T, Abesada-Terk G, Kim G, Alemany C, Faig D, Sharp P, Markham MJ, Shibata D, Malafa M, Jacobsen PB. Degree of Variability in Performance on Breast Cancer Quality Indicators: Findings From the Florida Initiative for Quality Cancer Care. J Oncol Pract. 2011 Jul;7(4):247-251. Pubmedid: 22043190.


• Sequist LV, Gettinger S, Senzer NN, Martins RG, J?nne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R, Hafeez N, Sweeney J, Walker JR, Fritz C, Ross RW, Grayzel D, Engelman JA, Borger DR, Paez G, Natale R. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol. 2010 Nov;28(33):4953-4960. Pubmedid: 20940188.


• Lee MC, Gray J, Han HS, Plosker S. Fertility and reproductive considerations in premenopausal patients with breast cancer. Cancer Control. 2010 Jul;17(3):162-172. Pubmedid: 20664513.


• Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song L, Rawal B, Schell MJ, Bepler G. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol. 2010 Apr;28(8):1387-1394. Pubmedid: 20142592. Pmcid: PMC3040065.


• Gray J, Sommers E, Alvelo-Rivera M, Robinson L, Bepler G. Neoadjuvant chemotherapy for resectable non-small-cell lung cancer. Oncology (Williston Park). 2009 Sep;23(10):879-886. Pubmedid: 19839429.


• Gray J, Mao J, Szabo E, Kelley M, Kurie J, Bepler G. Lung cancer chemoprevention: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest. 2007 Sep;132(3 Suppl):56S-68S. Pubmedid: 17873160.


• Gray J, Murren J, Sharma A, Kelley S, Detterbeck F, Bepler G. Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab. J Thorac Oncol. 2007 Jun;2(6):571-573. Pubmedid: 17545855.


• Gray J, Alberts W, Bepler G. Statins and lung cancer risk. Chest. 2007 May;131(5):1274-1275. Pubmedid: 17494775.


• Nanjundan M, Nakayama Y, Cheng KW, Lahad J, Liu J, Lu K, Kuo WL, Smith-McCune K, Fishman D, Gray JW, Mills GB. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res. 2007 Apr;67(7):3074-3084. Pubmedid: 17409414.


• Lancaster J, Carney M, Gray J, Myring J, Gumbs C, Sampson J, Wheeler D, France E, Wiseman R, Harper P, Futreal P. BRCA1 and BRCA2 in breast cancer families from Wales: moderate mutation frequency and two recurrent mutations in BRCA1. Br J Cancer. 1998 Dec;78(11):1417-1420. Pubmedid: 9836472 .

Dr. Jhanelle Gray is a medical oncologist at the Moffitt Cancer Center.  She specializes in treating cancers of the breast, lung and thymus.

A Florida native, Dr. Gray enjoys the opportunity to practice locally after completing medical school and residency training in the New England area.  She first came to Moffitt for a fellowship in medical oncology and appreciates the center’s outstanding reputation for advancing cancer research and the multi-disciplinary approach to patient care that fosters a spirit of camaraderie among physicians.

Dr. Gray believes in empowering patients by providing the necessary information and recommendations that will help them make the right decisions to meet their needs.   She is continually impressed by her patients’ courage in the face of adversity and is motivated to make a difference in their lives.

Dr. Gray’s research interests include novel therapies.  She is involved in early-stage clinical trials at the national level with the Southwest Oncology Group and through Moffitt-initiated studies.  Moffitt’s emphasis on translational research benefits patients by turning basic science research in the lab into new clinical advances that improve outcomes and quality of life.  In addition, Dr. Gray reports that Moffitt is making great strides toward understanding the molecular and genetic factors that will allow each patient to have a personalized care plan.